{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001678","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.858081+00:00","generated_at":"2026-05-24T05:28:06.608038+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Cassava Sciences simufilam Phase 3 trial fails all endpoints; Alzheimer's program discontinued","bullets":["Phase 3 REFOCUS-ALZ failed all co-primary, secondary, and biomarker endpoints.","Simufilam showed no significant difference vs placebo on ADAS-COG12 or ADCS-ADL; p-values 0.37-0.67 and 0.16-0.23.","Cassava will discontinue all simufilam Alzheimer's development by Q2 2025.","Company had $128.6M cash at Dec 31, 2024; exploring TSC-related epilepsy."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001678","json":"https://secwatch.observer/filing/0001171843-25-001678.json","markdown":"https://secwatch.observer/filing/0001171843-25-001678.md","text":"https://secwatch.observer/filing/0001171843-25-001678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/0001171843-25-001678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:28:06.608038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}